Unicycive Therapeutics

UNCY · NASDAQ

$3.80+$0.29 (+8.26%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $3.51

About UNCY

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The company is headquartered in Los Altos, California and currently employs 21 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Employees: 21
Headquarters: Los Altos, California
Listed: Jun 17, 2021
Sector: Health Care
Industry: Biotechnology
Website: unicycive.com

Leadership

Unicycive Therapeutics executives
Name	Title	Since	Age
Shalabh Gupta	—	2016	52
John Townsend	—	—	63
Pramod Gupta	—	—	65
Doug Jermasek	—	—	64
Gaurav Aggarwal	—	—	52
Saraswati Kenkare-Mitra	—	—	57
Sandeep Laumas	—	—	57

Similar companies

Companies in the same industry as Unicycive Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.